Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCTB35 in R/R B-cell Non-Hodgkin Lymphoma
NCT06318884Phase 1Not yet recruiting
- Sponsor
- Sinocelltech Group Limited
- Start
- Apr 2024
- Primary completion
- Oct 2026
- Modality
- Bispecific Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SCTB35 in B-cell non-Hodgkin lymphoma, sponsored by Sinocelltech Group Limited. Primary endpoints: Dose Limiting Toxicity at 21 days, Incidence Rate of Adverse Events up to 3 years and 1 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
SCTB35
03
Conditions
B-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT06318884.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06318884.